Bausch Health Cos (NYSE:BHC) Earns Equal Weight Rating from Analysts at Barclays

Barclays started coverage on shares of Bausch Health Cos (NYSE:BHC) in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage issued an equal weight rating and a $8.00 target price on the stock.

A number of other equities research analysts have also weighed in on BHC. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bausch Health Cos in a research note on Monday. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.67.

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock opened at $6.83 on Monday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of 7.04 and a beta of 0.41. The company has a fifty day moving average of $6.45 and a 200-day moving average of $6.45. Bausch Health Cos has a 52-week low of $4.25 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new position in Bausch Health Cos during the 1st quarter valued at approximately $27,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after acquiring an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares during the period. Alpha Wealth Funds LLC purchased a new stake in Bausch Health Cos in the second quarter worth $65,000. Finally, Stratos Wealth Advisors LLC bought a new stake in Bausch Health Cos in the second quarter valued at $67,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.